UPCC 13324: A Phase 3 Randomized, Open-Label Study to Evaluate the Efficacy and Safety of Petosemtamab Plus Pembrolizumab vs Pembrolizumab in First-Line Treatment of Recurrent or Metastatic PD-L1+ Head and Neck Squamous Cell Carcinoma.

This is a phase 3 randomized, open-label study to evaluate the efficacy and safety of petosemtamab plus pembrolizumab vs pembrolizumab for the first-line (1L) treatment of recurrent or metastatic, programmed cell death protein ligand 1+ (PD-L1+) head and neck squamous cell carcinoma (HNSCC) in patients with combined positive score (CPS) 1.

We would like to rely on Advarra as the IRB of record for this study.

You may be eligible for this study if you meet the following criteria:

• Conditions:
  Medical Research
• Age: - 99 Years
• Gender: All